Follow the people · Insider
Laura Lee Sandler
Laura Lee Sandler files insider transactions with the SEC as a chief operating officer of Oruka Therapeutics (ORKA). We hold 7 disclosed purchases and sales filed since 1 July 2025, 3 of them in the last 90 days.
- Files forORKA
- Disclosed buys and sells7 in all, 3 in the last 90 days
- Last disclosure1 September 2026
Positions held
1 post we hold — a term names its own dates; a run of filings only says when they filed- Filed 1 July 2025 — 1 September 2026Chief Operating Officer · Oruka Therapeutics (ORKA)43 Form 4 lines · source: SEC Form 4
Everything they disclosed
43 entries, newest first — one per disclosure report, one per Form 4 line- exercised options over 5,000 shares of Oruka TherapeuticsSEC Form 41 September 2026Common Stock · traded 1 September 2026 · filed 1 September 2026
- ▼ sold on the open market 1,000 shares of Oruka TherapeuticsSEC Form 41 September 2026Common Stock · traded 1 September 2026 · filed 1 September 2026
- ▼ sold on the open market 4,000 shares of Oruka TherapeuticsSEC Form 41 September 2026Common Stock · traded 1 September 2026 · filed 1 September 2026
- exercised options over 5,000 shares of Oruka Therapeutics (a derivative holding)SEC Form 41 September 2026Employee Warrant (right to buy) · traded 1 September 2026 · filed 1 September 2026
- exercised options over 5,000 shares of Oruka TherapeuticsSEC Form 41 July 2026Common Stock · traded 1 July 2026 · filed 1 July 2026
- ▼ sold on the open market 2,237 shares of Oruka TherapeuticsSEC Form 41 July 2026Common Stock · traded 1 July 2026 · filed 1 July 2026
- ▼ sold on the open market 2,263 shares of Oruka TherapeuticsSEC Form 41 July 2026Common Stock · traded 1 July 2026 · filed 1 July 2026
- ▼ sold on the open market 500 shares of Oruka TherapeuticsSEC Form 41 July 2026Common Stock · traded 1 July 2026 · filed 1 July 2026
- exercised options over 5,000 shares of Oruka Therapeutics (a derivative holding)SEC Form 41 July 2026Employee Warrant (right to buy) · traded 1 July 2026 · filed 1 July 2026
- ▼ sold on the open market 600 shares of Oruka TherapeuticsSEC Form 415 June 2026Common Stock · traded 15 June 2026 · filed 15 June 2026
- exercised options over 5,000 shares of Oruka TherapeuticsSEC Form 41 May 2026Common Stock · traded 1 May 2026 · filed 1 May 2026
- ▼ sold on the open market 2,200 shares of Oruka TherapeuticsSEC Form 41 May 2026Common Stock · traded 1 May 2026 · filed 1 May 2026
- ▼ sold on the open market 1,800 shares of Oruka TherapeuticsSEC Form 41 May 2026Common Stock · traded 1 May 2026 · filed 1 May 2026
- ▼ sold on the open market 300 shares of Oruka TherapeuticsSEC Form 41 May 2026Common Stock · traded 1 May 2026 · filed 1 May 2026
- ▼ sold on the open market 400 shares of Oruka TherapeuticsSEC Form 41 May 2026Common Stock · traded 1 May 2026 · filed 1 May 2026
- ▼ sold on the open market 200 shares of Oruka TherapeuticsSEC Form 41 May 2026Common Stock · traded 1 May 2026 · filed 1 May 2026
- ▼ sold on the open market 100 shares of Oruka TherapeuticsSEC Form 41 May 2026Common Stock · traded 1 May 2026 · filed 1 May 2026
- exercised options over 5,000 shares of Oruka Therapeutics (a derivative holding)SEC Form 41 May 2026Employee Warrant (right to buy) · traded 1 May 2026 · filed 1 May 2026
- ▼ sold on the open market 600 shares of Oruka TherapeuticsSEC Form 417 March 2026Common Stock · traded 16 March 2026 · filed 17 March 2026
- ▼ sold on the open market 600 shares of Oruka TherapeuticsSEC Form 417 March 2026Common Stock · traded 16 March 2026 · filed 17 March 2026
- exercised options over 5,000 shares of Oruka TherapeuticsSEC Form 42 March 2026Common Stock · traded 2 March 2026 · filed 2 March 2026
- ▼ sold on the open market 2,325 shares of Oruka TherapeuticsSEC Form 42 March 2026Common Stock · traded 2 March 2026 · filed 2 March 2026
- ▼ sold on the open market 2,675 shares of Oruka TherapeuticsSEC Form 42 March 2026Common Stock · traded 2 March 2026 · filed 2 March 2026
- exercised options over 5,000 shares of Oruka Therapeutics (a derivative holding)SEC Form 42 March 2026Employee Warrant (right to buy) · traded 2 March 2026 · filed 2 March 2026
- exercised options over 5,000 shares of Oruka Therapeutics (a derivative holding)SEC Form 42 March 2026Employee Warrant (right to buy) · traded 2 March 2026 · filed 2 March 2026
- exercised options over 5,000 shares of Oruka TherapeuticsSEC Form 42 March 2026Common Stock · traded 2 March 2026 · filed 2 March 2026
- ▼ sold on the open market 2,325 shares of Oruka TherapeuticsSEC Form 42 March 2026Common Stock · traded 2 March 2026 · filed 2 March 2026
- ▼ sold on the open market 2,675 shares of Oruka TherapeuticsSEC Form 42 March 2026Common Stock · traded 2 March 2026 · filed 2 March 2026
- was granted 32,500 shares of Oruka TherapeuticsSEC Form 423 January 2026Common Stock · traded 23 January 2026 · filed 23 January 2026
- was granted 130,000 shares of Oruka Therapeutics (a derivative holding)SEC Form 423 January 2026Employee Stock Option (right to buy) · traded 23 January 2026 · filed 23 January 2026
- was granted 130,000 shares of Oruka Therapeutics (a derivative holding)SEC Form 423 January 2026Employee Stock Option (right to buy) · traded 23 January 2026 · filed 23 January 2026
- was granted 32,500 shares of Oruka TherapeuticsSEC Form 423 January 2026Common Stock · traded 23 January 2026 · filed 23 January 2026
- exercised options over 5,000 shares of Oruka TherapeuticsSEC Form 42 January 2026Common Stock · traded 2 January 2026 · filed 2 January 2026
- ▼ sold on the open market 8,748 shares of Oruka TherapeuticsSEC Form 42 January 2026Common Stock · traded 2 January 2026 · filed 2 January 2026
- ▼ sold on the open market 3,144 shares of Oruka TherapeuticsSEC Form 42 January 2026Common Stock · traded 2 January 2026 · filed 2 January 2026
- exercised options over 5,000 shares of Oruka Therapeutics (a derivative holding)SEC Form 42 January 2026Employee Warrant (right to buy) · traded 2 January 2026 · filed 2 January 2026
- ▼ sold on the open market 1,108 shares of Oruka TherapeuticsSEC Form 42 January 2026Common Stock · traded 2 January 2026 · filed 2 January 2026
- exercised options over 5,000 shares of Oruka Therapeutics (a derivative holding)SEC Form 42 January 2026Employee Warrant (right to buy) · traded 2 January 2026 · filed 2 January 2026
- exercised options over 5,000 shares of Oruka TherapeuticsSEC Form 42 January 2026Common Stock · traded 2 January 2026 · filed 2 January 2026
- ▼ sold on the open market 8,748 shares of Oruka TherapeuticsSEC Form 42 January 2026Common Stock · traded 2 January 2026 · filed 2 January 2026
- ▼ sold on the open market 3,144 shares of Oruka TherapeuticsSEC Form 42 January 2026Common Stock · traded 2 January 2026 · filed 2 January 2026
- ▼ sold on the open market 1,108 shares of Oruka TherapeuticsSEC Form 42 January 2026Common Stock · traded 2 January 2026 · filed 2 January 2026
- was granted 25,000 shares of Oruka Therapeutics (a derivative holding)SEC Form 41 July 2025Employee Stock Option (right to buy) · traded 1 July 2025 · filed 1 July 2025
Positions come from the unitedstates/congress-legislators roster, the Office of Government Ethics and the SEC’s Form 4 index. Every disclosed line names its own source and links the document the government published; we print what the filing says and never a price we did not read from it. Headlines and links come from the GDELT Global Knowledge Graph — the story stays with the publisher. The portrait, where we have one, is the public-domain Congressional Bioguide photograph.